Shelby Olds, MD
Internal Medicine · Bristol, TNNPI 1205832169
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 644 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 644 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Novo Nordisk$1K
- GSK$866
- Amgen$718
- Takeda Pharmaceuticals U.S.A., Inc.$484
- plus $3K from 35 others
Across 15 payments — averaging $5269.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$50K
- Astrazeneca UK Limited$16K
- H. Lundbeck A S$13K
What the payments were for
- Food & beverage$9,914100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,937 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 167 | $193,216 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $127,538 |
| EliquisApixaban | 113 | $92,338 |
| MounjaroTirzepatide | 71 | $72,503 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 87 | $71,551 |
| TrulicityDulaglutide | 49 | $69,630 |
| Repatha SureclickEvolocumab | 63 | $51,046 |
| JanuviaSitagliptin Phosphate | 66 | $50,783 |
| XareltoRivaroxaban | 46 | $48,823 |
| FarxigaDapagliflozin Propanediol | 60 | $43,101 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $39,766 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $38,178 |
| TradjentaLinagliptin | 49 | $33,501 |
| LinzessLinaclotide | 43 | $29,236 |
| NexletolBempedoic Acid | 46 | $20,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,112 | $193,216167 claims |
| Lilly USA, LLCMounjaro, Trulicity | $228 | $142,134120 claims |
| GSKTrelegy Ellipta | $866 | $127,538145 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $2,164 | $119,722158 claims |
| PfizerEliquis | $180 | $92,338113 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua), Janumet Xr | $101 | $87,150115 claims |
| AbbVieLinzess, Synthroid, Restasis, Savella | $1,764 | $58,925308 claims |
| Johnson & JohnsonXarelto, Invokana | $192 | $58,15159 claims |
| Boehringer IngelheimTradjenta, Jardiance | $99 | $47,62363 claims |
| Esperion Therapeutics, Inc.Nexletol | $121 | $20,12646 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $484 | $12,76513 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $14 | $10,23031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Bristol
- Nathan GargusBristol$22K
- Bernard GrunstraBristol$16K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Dennis DeruelleKnoxville$263K
- Devin ShermanFranklin$191K
- Lewis HagoodKnoxville$143K
- Temidayo AbeNashville$113K
- Kenya KozawaSweetwater$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.